PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q4 2018 13F Holders as of 31 Dec 2018

Type / Class
Equity / COM
Total 13F shares
74,064,915
Share change
-3,830,395
Total reported value
$310,896,095
Put/Call ratio
102%
Price per share
$4.20
Number of holders
140
Value change
-$25,616,323
Number of buys
69
Number of sells
64

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q4 2018

As of 31 Dec 2018, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 140 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 74,064,915 shares. The largest 10 holders included BlackRock Inc., ARMISTICE CAPITAL, LLC, STATE STREET CORP, Point72 Asset Management, L.P., EAGLE ASSET MANAGEMENT INC, FARALLON CAPITAL MANAGEMENT LLC, CARILLON TOWER ADVISERS, INC., Vanguard Group Inc, FEDERATED INVESTORS INC /PA/, and RICE HALL JAMES & ASSOCIATES, LLC. This page lists 140 institutional shareholders reporting positions in this security for the Q4 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.